{"title":"Healthcare","description":null,"products":[{"product_id":"global-preventive-and-predictive-healthcare-market","title":"Global Preventive and Predictive Healthcare Market 2026","description":"\u003ch2\u003eMarket at a Glance\u003c\/h2\u003e\u003cp\u003eThe global preventive and predictive healthcare market is estimated at approximately \u003cstrong\u003eUSD 304 billion in 2025\u003c\/strong\u003e and is forecast to reach approximately \u003cstrong\u003eUSD 442 billion by 2032\u003c\/strong\u003e, representing a \u003cstrong\u003e5.5% CAGR\u003c\/strong\u003e. Established screening and preventive services provide the revenue foundation, while continuous monitoring expands the role of recurring devices, consumables and associated services.\u003c\/p\u003e\u003cp\u003eThis report examines how early detection, risk identification and preventive intervention translate into commercial revenue. It connects market size and regional outlooks with participant strategies, purchasing channels and payment models.\u003c\/p\u003e\u003ch2\u003eEstablished services anchor demand; monitoring expands faster\u003c\/h2\u003e\u003cp\u003eScreening, health examinations and preventive services account for approximately two-thirds of market revenue in 2025 and are expected to generate around 60% of incremental revenue through 2032. Continuous monitoring gains share as sustained use and consumable replenishment support recurring demand.\u003c\/p\u003e\u003cp\u003eThe commercial opportunity extends beyond adoption of new tests or algorithms. Repeat screening, completed diagnostic pathways, paid clinical cases and sustained participation determine how demand becomes revenue. The report examines these differences across laboratory testing, imaging AI, coronary analytics, vaccines and digital prevention.\u003c\/p\u003e\u003ch2\u003eRegional opportunity depends on payment and delivery\u003c\/h2\u003e\u003cp\u003eNorth America is projected to remain the largest revenue market. Europe and Asia Pacific are expected to be similar in size by 2032, each representing approximately 29% of global revenue. Organized screening and public procurement shape European demand, while broader examination coverage and monitoring adoption support Asia Pacific growth.\u003c\/p\u003e\u003cp\u003eRegional analysis covers insurance reimbursement, self-pay, employer contracts and public programs, highlighting how purchasing arrangements influence market entry and recurring service delivery.\u003c\/p\u003e\u003ch2\u003eWhat the report covers\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket size and structure:\u003c\/strong\u003e Global estimates for 2025 and forecasts for 2032, with business-level revenue breakdowns for screening and preventive services, vaccine products, and continuous monitoring devices and directly associated services.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegional outlook:\u003c\/strong\u003e North America, Europe, Asia Pacific and other regions, including market values, shares and 2025–2032 growth rates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEarly detection:\u003c\/strong\u003e Molecular colorectal screening, multicancer early detection and screening imaging AI.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRisk identification:\u003c\/strong\u003e Coronary analytics, clinical risk workflows, continuous monitoring and digital biomarkers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePreventive interventions:\u003c\/strong\u003e Employer and health-plan programs, public prevention services, engagement, retention and delivery economics.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive landscape:\u003c\/strong\u003e Testing platforms, imaging AI businesses, laboratory networks, examination providers and digital health companies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePayment models:\u003c\/strong\u003e Testing fees, paid-case analytics, software subscriptions, member service fees, public procurement and performance-linked payments.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eParticipants examined\u003c\/h2\u003e\u003cp\u003eCoverage includes Abbott\/Exact Sciences, Guardant Health, GRAIL, Geneoscopy\/Labcorp, Heartflow, Cleerly, Lunit, RadNet\/DeepHealth, Dexcom\/Oura, Omada Health, Virta Health, Quest Diagnostics, Meinian Onehealth, Terveystalo\/Feelgood and Sonde Health. Vaccine coverage includes GSK, Merck\/MSD, Pfizer and Sanofi.\u003c\/p\u003e\u003ch2\u003eReport contents\u003c\/h2\u003e\u003col\u003e\n\u003cli\u003eMarket Development and Value Creation\u003c\/li\u003e\n\u003cli\u003eEarly Detection: Established Screening and Multicancer Testing\u003c\/li\u003e\n\u003cli\u003eRisk Identification and Clinical Workflows\u003c\/li\u003e\n\u003cli\u003ePreventive Interventions and Service Revenue\u003c\/li\u003e\n\u003cli\u003eKey Participant Strategies and Competitive Landscape\u003c\/li\u003e\n\u003cli\u003eRegional Market Size and Payment Models\u003c\/li\u003e\n\u003cli\u003eCommercial Pathways and Growth Conditions\u003c\/li\u003e\n\u003c\/ol\u003e\u003ch2\u003eDelivery details\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eFormat:\u003c\/strong\u003e English PDF\u003cbr\u003e\u003cstrong\u003eLength:\u003c\/strong\u003e 19 pages\u003cbr\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e October 2026\u003cbr\u003e\u003cstrong\u003eMarket sizing:\u003c\/strong\u003e 2025 estimates and 2032 forecasts\u003cbr\u003e\u003cstrong\u003eIncluded:\u003c\/strong\u003e Six tables and 47 references\u003c\/p\u003e\u003cp\u003eThe report supports market opportunity assessment, partnership evaluation and commercial planning by connecting category growth with the practical conditions for adoption, payment and continuing use.\u003c\/p\u003e","brand":"Tanalyze","offers":[{"title":"Default Title","offer_id":50129931337883,"sku":null,"price":175.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0729\/4130\/6011\/files\/global-preventive-and-predictive-healthcare-cover-market-research.jpg?v=1794302584"},{"product_id":"global-diabetes-care-devices-market","title":"Global Diabetes Care Devices Market 2026","description":"\u003ch2\u003eMarket at a Glance\u003c\/h2\u003e\n\u003cp\u003eThe global diabetes care devices market is forecast to reach \u003cstrong\u003eUSD 40.69 billion by 2031\u003c\/strong\u003e, up from an estimated USD 25.1 billion in 2025, representing an \u003cstrong\u003e8.4% CAGR\u003c\/strong\u003e. Continuous glucose monitoring and insulin pumps are reshaping revenue around recurring consumables, automated delivery and connected treatment.\u003c\/p\u003e\n\u003ch2\u003eInsulin pumps grow fastest; CGM delivers the largest revenue gain\u003c\/h2\u003e\n\u003cp\u003eInsulin pumps and infusion consumables are forecast to grow at \u003cstrong\u003e11.5% annually from 2025 to 2031\u003c\/strong\u003e, supported by automated insulin delivery and conversion from injections. CGM expands at 9.8% and contributes the largest absolute increase in revenue. Together, these two businesses are projected to account for \u003cstrong\u003e87.8% of market revenue in 2031\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eTraditional fingerstick monitoring retains a role in affordable and supplementary testing, but migration among frequent testers puts pressure on test-strip revenue. Connected insulin pens provide another route to integrating dose records with glucose data. These different adoption paths make reimbursement, compatibility and sustained use central to commercial performance.\u003c\/p\u003e\n\u003ch2\u003eRecurring use changes the competitive equation\u003c\/h2\u003e\n\u003cp\u003eSensor replenishment, disposable pods and infusion supplies extend revenue beyond the initial device purchase. Established suppliers benefit from distribution reach and reimbursement access, while new platforms compete on wearability, ease of use and system compatibility. Patient retention and reliable supply influence how adoption translates into repeat revenue.\u003c\/p\u003e\n\u003cp\u003eNorth America is expected to remain the largest regional market. Asia Pacific is forecast to grow faster, as access expands across markets with different reimbursement arrangements and affordability constraints. The report connects these regional differences with product adoption, payment pathways and manufacturer strategies.\u003c\/p\u003e\n\u003ch2\u003eWhat the report covers\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnnual market sizing:\u003c\/strong\u003e Global revenue estimates for 2025 and annual forecasts for 2026–2031, with four product categories, market totals and category growth rates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct markets:\u003c\/strong\u003e CGM devices and consumables; SMBG meters, strips and associated lancing accessories; insulin pumps and infusion consumables; insulin pen hardware and smart accessories.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegional analysis:\u003c\/strong\u003e North America, Europe, Asia Pacific and other regions, including 2025 and 2031 revenue, shares and growth rates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTechnology and adoption:\u003c\/strong\u003e Automated insulin delivery, patch and durable pumps, implantable monitoring, multi-analyte sensing, connected injection management and the development status of alternative approaches.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetition and commercial models:\u003c\/strong\u003e Supplier strategies, system partnerships, reimbursement, recurring consumables, manufacturing and user retention.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTreatment dynamics:\u003c\/strong\u003e Type 1 and type 2 diabetes pathways, digital care integration and the implications of GLP-1 medicines for device use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eMarket revenue measures manufacturer-level device value. Insulin pen figures cover hardware and smart accessories, including the estimated hardware component of prefilled pens, rather than the insulin they contain.\u003c\/p\u003e\n\u003ch2\u003eParticipants examined\u003c\/h2\u003e\n\u003cp\u003eCoverage includes Abbott, Dexcom, Insulet, MiniMed, Tandem, Beta Bionics, Senseonics, Roche, Ascensia\/PHC, LifeScan, Sinocare, mylife Diabetes Care, Ypsomed, Sequel Med Tech, Diabeloop, Tidepool, Novo Nordisk, Sanofi and Eli Lilly.\u003c\/p\u003e\n\u003ch2\u003eReport contents\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eMarket Overview\u003c\/li\u003e\n\u003cli\u003eGlobal Market Size and Growth\u003c\/li\u003e\n\u003cli\u003eProduct Markets\u003c\/li\u003e\n\u003cli\u003eCompetitive Landscape and Company Strategies\u003c\/li\u003e\n\u003cli\u003eDemand, Reimbursement and Business Models\u003c\/li\u003e\n\u003cli\u003eRegional Markets\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eDelivery details\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eFormat:\u003c\/strong\u003e English PDF\u003cbr\u003e\u003cstrong\u003eLength:\u003c\/strong\u003e 16 pages\u003cbr\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e October 2026\u003cbr\u003e\u003cstrong\u003eIncluded:\u003c\/strong\u003e Six tables, three data visualizations and 32 references\u003cbr\u003e\u003cstrong\u003eDelivery:\u003c\/strong\u003e Automatic digital download after payment\u003c\/p\u003e","brand":"Tanalyze","offers":[{"title":"Default Title","offer_id":50130549244059,"sku":null,"price":175.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0729\/4130\/6011\/files\/global-diabetes-care-devices-cover.jpg?v=1794304532"},{"product_id":"global-medical-polymeric-membranes-market","title":"Global Medical Polymeric Membranes Market, 2025–2032","description":"\u003ch2\u003eMarket at a Glance\u003c\/h2\u003e\n\u003cp\u003eThe global medical polymeric membranes market is forecast to reach USD 10.86 billion by 2032. Biopharmaceutical filtration is expanding faster than dialysis, as biologics production increases demand for high-performance separation and validated consumables. Dialysis remains a substantial source of recurring purchases, while process compatibility, product recovery and reliable supply increasingly shape competition.\u003c\/p\u003e\n\u003ch2\u003eMarket Outlook\u003c\/h2\u003e\n\u003cp\u003eMedical polymeric membranes connect two distinct demand bases: recurring clinical treatment and pharmaceutical production. Dialysis generates repeat purchases tied to treatment activity, while bioprocessing customers select membranes for specific requirements in concentration, purification, sterilizing filtration and virus removal. The commercial value of these products extends beyond membrane area to the performance of the complete module within its intended application.\u003c\/p\u003e\n\u003cp\u003eBiopharmaceutical membranes and modules are projected to become the larger application group during the forecast period. Higher throughput, low protein adsorption and dependable retention help protect valuable production batches, while integration with single-use assemblies expands the role of filtration suppliers within manufacturing workflows. Dialysis continues to provide an established consumables base, with differentiation centered on selectivity, blood compatibility and manufacturing consistency.\u003c\/p\u003e\n\u003cp\u003eCompetition spans clinical specialists, integrated bioprocessing platforms and membrane component suppliers. Qualification requirements and the cost of changing validated processes support durable customer relationships. At the same time, procurement pressure and gains in filtration efficiency mean that greater treatment or production activity does not translate directly into proportional membrane revenue growth.\u003c\/p\u003e\n\u003ch2\u003eReport Coverage\u003c\/h2\u003e\n\u003cp\u003eThis 16-page English PDF provides annual market estimates and forecasts for 2025–2032, supported by analysis of applications, materials, separation processes, regional demand and supplier positioning. The 2025 figures are estimates; 2026–2032 figures are forecasts.\u003c\/p\u003e\n\u003cp\u003eMarket sizing measures manufacturers' net sales of medical polymeric membranes and membrane modules, including integral module housings and encapsulation. Values are presented in USD billion.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnnual global revenue estimates and forecasts, with application, material, process and regional breakdowns.\u003c\/li\u003e\n\u003cli\u003eGrowth rates and shifts in market composition across the forecast period.\u003c\/li\u003e\n\u003cli\u003eClinical filtration, dialysis and biopharmaceutical production demand.\u003c\/li\u003e\n\u003cli\u003eMembrane chemistry, structures, surface engineering and performance development.\u003c\/li\u003e\n\u003cli\u003eSupplier capabilities, validation requirements, procurement and supply-chain considerations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eMarket Segmentation\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eDialysis modules\u003c\/li\u003e\n\u003cli\u003eBiopharmaceutical membranes and modules\u003c\/li\u003e\n\u003cli\u003eOther clinical and diagnostic membranes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFunctional membrane material\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003ePSU\/PES family\u003c\/li\u003e\n\u003cli\u003eCellulose and derivatives\u003c\/li\u003e\n\u003cli\u003eFluoropolymers\u003c\/li\u003e\n\u003cli\u003eOther polymers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSeparation process and function\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eDialysis and hemodiafiltration\u003c\/li\u003e\n\u003cli\u003eUltrafiltration and diafiltration\u003c\/li\u003e\n\u003cli\u003eMicrofiltration and sterilizing filtration\u003c\/li\u003e\n\u003cli\u003eVirus removal\u003c\/li\u003e\n\u003cli\u003eOther functions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRegion\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eAmericas\u003c\/li\u003e\n\u003cli\u003eEurope\u003c\/li\u003e\n\u003cli\u003eAsia Pacific\u003c\/li\u003e\n\u003cli\u003eMiddle East and Africa\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCompetitive Landscape\u003c\/h2\u003e\n\u003cp\u003eThe report examines how clinical manufacturing scale, bioprocessing workflow coverage and specialist membrane expertise create different competitive positions. It discusses product portfolios, selected corporate developments, capacity investment, customer qualification and regional supply, with company profiles organized around relevant activities and commercial capabilities.\u003c\/p\u003e\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cp\u003eExecutive Summary\u003cbr\u003e1. Market Scope and Commercial Structure\u003cbr\u003e2. Global Market Size and Growth Drivers\u003cbr\u003e3. Application Demand and Product Development\u003cbr\u003e4. Materials and Separation Technologies\u003cbr\u003e5. Regional Demand and Supply\u003cbr\u003e6. Key Participants and Competitive Landscape\u003cbr\u003e7. Quality, Supply Chains and Commercial Value\u003cbr\u003eReferences\u003cbr\u003eDisclaimer\u003c\/p\u003e\n\u003ch2\u003eCompanies Covered\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAsahi Kasei Life Science\u003c\/li\u003e\n\u003cli\u003eAsahi Kasei Medical\u003c\/li\u003e\n\u003cli\u003eB. Braun\u003c\/li\u003e\n\u003cli\u003eCytiva \/ Pall Life Sciences\u003c\/li\u003e\n\u003cli\u003eFresenius Medical Care\u003c\/li\u003e\n\u003cli\u003eGVS\u003c\/li\u003e\n\u003cli\u003eJiangxi Sanxin Medtec\u003c\/li\u003e\n\u003cli\u003eMerck\u003c\/li\u003e\n\u003cli\u003eNipro\u003c\/li\u003e\n\u003cli\u003eRepligen\u003c\/li\u003e\n\u003cli\u003eSartorius\u003c\/li\u003e\n\u003cli\u003eThermo Fisher Scientific\u003c\/li\u003e\n\u003cli\u003eToray\u003c\/li\u003e\n\u003cli\u003eVantive\u003c\/li\u003e\n\u003cli\u003eWeigao Blood Purification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFormat:\u003c\/strong\u003e English PDF, 16 pages.\u003cbr\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e November 2026.\u003cbr\u003e\u003cstrong\u003eCoverage:\u003c\/strong\u003e 2025–2032.\u003c\/p\u003e","brand":"StrategyHelix","offers":[{"title":"Default Title","offer_id":50144287817883,"sku":null,"price":275.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0729\/4130\/6011\/files\/global-medical-polymeric-membranes-cover.jpg?v=1794361699"}],"url":"https:\/\/strategyhelix.com\/collections\/healthcare.oembed","provider":"StrategyHelix","version":"1.0","type":"link"}